The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

Among adolescents with asthma and overweight or obesity, the relative risk for acute asthma exacerbations was significantly reduced with GLP-1 receptor agonist use vs. nonpharmacological weight ...

A 45-year-old woman presents with long-standing exertional dyspnea, wheezing, and intermittent dry cough, which has been ongoing for over the past 10 years.

Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks. The European Commission ...

Asthma action plans help maintain good asthma control by outlining symptoms, triggers, medications, and emergency contacts. Avoiding triggers, such as allergens and tobacco smoke, can help prevent ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma companies' clinical development programmes in return for royalties on ...

"Overweight and obesity are established risk factors that contribute to greater severity and more frequent exacerbations of asthma among adolescents," they explained. GLP-1 agents ...

The treatment of chronic obstructive pulmonary disease (COPD) has been guided for decades by robust clinical practice guidelines (CPGs), such as NICE1 and GesEPOC,2 as well as international ...

The Ministry of National Education and Sports issued a decision, setting out the list of prohibited substances and methods in sport for 2026.